Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafluprost/Timolol FDC vs Concomitant in Glaucoma or Ocular Hypertension
NCT01306461Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Mar 2011
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tafluprost + timolol in open-angle glaucoma (OAG), ocular hypertension, sponsored by Santen Pharmaceutical. Started Mar 2011; status: completed.
02
Drugs
tafluprost + timolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT01306461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01306461.